Physician profile
Bhavin Patel
NPI 1154709814
$16,826.64
in general payments reported to CMS, 2019-2025
27 companies · $9,168 in 2025
The $9,168 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.18 · 2022: $735 · 2023: $1,694 · 2024: $5,177 · 2025: $9,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,152 · Education: $4,779 · Travel and Lodging: $3,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,152.13 |
| Education | $4,778.96 |
| Travel and Lodging | $3,108.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,192.50 | 2025 | |
| Axonics, INC. | $3,959.12 | 2023-2024 | Axonics, Bulkamid |
| Abbvie INC. | $2,716.45 | 2021-2025 | |
| Janssen Biotech, INC. | $573.12 | 2022-2025 | Stelara, Tremfya, Simponi |
| Enterra Medical, INC. | $424.91 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $325.55 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.01 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $253.95 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $238.92 | 2023-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $216.24 | 2025 | |
| Celltrion USA INC. | $199.90 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $186.69 | 2023-2025 | Dupixent |
| Genzyme Corporation | $172.10 | 2023-2025 | |
| Lilly USA, LLC | $164.71 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $147.66 | 2025 | Axonics |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $134.39 | 2024-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $133.50 | 2025 | Stelara, Tremfya, Remicade |
| Qol Medical, LLC | $126.81 | 2025 | Sucraid |
| Celgene Corporation | $70.60 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $63.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $60.93 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $36.03 | 2023-2025 | Ocaliva |
| Novo Nordisk INC | $26.46 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $24.63 | 2024 | Terlivaz |
| Braintree Laboratories, INC. | $23.87 | 2024 | Suflave, Sutab |
| Daiichi Sankyo INC. | $23.14 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $17.45 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.